Abstract: Transdermal nanoemugels for systemic delivery of potent drugs like aromatase inhibitors letrozole and anastrozole are disclosed. The disclosed compositions may include gelling agent, surfactants, cosolvents, and oily components. The process of preparing the nanoemulgels is simple and the formation of nanoemulgels is spontaneous. Penetration enhancers are included in the compositions of the transdermal nanoemugels. The compositions have penetration power with emollient effects to the skin. The transdermal drug delivery system may be applied to skin in a single dose that produces pharmacologically effective blood concentration of the potent drug for one week or up to one month depending on the amount and thickness of the applied nanoemugels in the transdermal matrix patches. The nanoemulgels can be used for topical delivery of NSAID.

Abstract: The present invention provides a nanoparticle comprising: a core comprising a metal and/or a semiconductor; and a plurality of ligands covalently linked to the core, wherein said ligands comprise: at least one liver-targeting ligand, such as C2-alpha galactose; at least one payload ligand comprising a bioactive agent, such as maytansinoid DM1; and at least one dilution ligand comprising a poly(ethyleneglycol) (PEG) moiety, such as PEG COOH. Also provided are pharmaceutical compositions comprising the nanoparticle, and uses of the nanoparticle in methods of treatment of liver disorders, including liver cancers such as hepatocellular carcinoma (HCC).

Abstract: A pharmaceutical formulation comprising an erosion matrix comprising one or more fumaric acid esters as well as one or more rate-controlling agents, wherein erosion of said erosion matrix permits controlled release of said fumaric acid ester(s).

Abstract: Compounds, compositions, kits and methods for performing angiography related to ocular diseases, are disclosed.

Abstract: The present invention generally relates to targeted nanoparticle delivery to E-selectin- or P-selectin-positive cells or tissues. In particular, this invention discloses a method for preparing quinic acid-modified nanoparticles for targeted drug delivery to cancerous cells or tissues via E-selectin- or P-selectin-mediated transcytosis. The invention described herein also pertains to pharmaceutical compositions and methods for treating cancers.

Abstract: Embodiments herein described provide devices for identifying and collecting rare cells or cells which occur at low frequency in the body of a subject, such as, antigen-specific cells or disease-specific cells. More specifically, the devices are useful for trapping immune cells and the devices contain a physiologically-compatible porous polymer scaffold, a plurality of antigens, and an immune cell-recruiting agent, wherein the plurality of antigens and the immune cell recruiting agent attract and trap the immune cell in the device. Also provided are pharmaceutical compositions, kits, and packages containing such devices. Additional embodiments relate to methods for making the devices, compositions, and kits/packages. Further embodiments relate to methods for using the devices, compositions, and/or kits in the diagnosis or therapy of diseases such as autoimmune diseases or cancers.

Abstract: This invention concerns pharmaceutical compositions for administration via intramuscular or subcutaneous injection, comprising micro- or nanoparticles of the anti-TB compound bedaquiline, suspended in an aqueous pharmaceutically acceptable carrier, and the use of such pharmaceutical compositions in the treatment and prophylaxis of a pathogenic mycobacterial infection.

Abstract: Some embodiments relate to nanoparticle probes for the detection of disease states in a patient or for tissue engineering. In some embodiments, the nanoparticle probe comprises one or more slip bonds that bind to a cell surface structure. In some embodiments, the binding of the nanoparticle probe is selective. In some embodiments, the nanoparticle probe binds to cells having a certain maximum glycocalyx thickness.

Abstract: The invention relates stable compact low viscosity hair care compositions comprising: from about 20 weight % to about 45 weight % total surfactant; from about 2 weight % to about 25 weight % branched anionic surfactant with a tail having an alkyl chain with 12 to 18 carbon atoms; from about 5% weight % to about 30 weight % linear anionic surfactant with a tail having an alkyl chain with 12 to 18 carbon atom; from about 0.1 weight % to about 8 weight % of a viscosity reducing agent; from about 40 weight % to about 80 weight % of water; wherein the concentrated shampoo has Ratio of Linear anionic surfactant to Branched anionic surfactant of about 0.3 to about 5, wherein the concentrated shampoo has a viscosity of less than 3000 cP at 26.5° C.

Abstract: A method of detecting Pd2+ in an aqueous solution is described. The method involves mixing an Eu-based metal organic framework with the aqueous solution and measuring the amount of fluorescence quenching. The fluorescence quenching is specific to Pd2+ and also allows a 44 ppb detection limit of Pd2+. The Eu-based metal organic framework may be treated with a metal chelator and reused for sensitive detection of Pd2+.

Abstract: The present invention relates to a method of raising an aquatic animal in an aquaculture system, the method comprising: (a) contacting the aquaculture system with a water-treatment composition over a first period of time, wherein the water-treatment composition comprises Bacillus subtilis, Bacillus amyloliquefaciens, Bacillus licheniformis, Bacillus pumilus, Bacillus mojavensis, Pediococcus acidilactici, Pediococcus pentosaceus, and Lactobacillus plantarum; and (b) contacting the aquaculture system with a feed additive composition to feed the aquatic animal over a second period of time, wherein the feed additive composition comprises Pediococcus acidilactici, Pediococcus pentosaceus, Lactobacillus plantarum, and Bacillus subtilis 34 KLB.

Abstract: This invention provides solid substrates for promoting cell or tissue growth or restored function, which solid substrate is characterized by a specific fluid uptake capacity value of at least 75%, which specific fluid uptake capacity value is determined by establishing a spontaneous fluid uptake value divided by a total fluid uptake value. This invention also provides solid substrates for promoting cell or tissue growth or restored function, which solid substrate is characterized by having a contact angle value of less than 60 degrees, when in contact with a fluid. This invention also provides solid substrates for promoting cell or tissue growth or restored function, which said substrate is characterized by a substantial surface roughness (Ra) as measured by scanning electron microscopy or atomic force microscopy. The invention also provides for processes for selection of an optimized coral-based solid substrate for promoting cell or tissue growth or restored function and applications of the same.

Abstract: A light emitter is formed from nanoparticles including a compound semiconductor containing an Ag component, In component, and Se component. The peak wavelength of the emission intensity falls within the range of 700 to 1400 nm, and the half-value width ?H for the peak wavelength is 100 nm or less. The light emitted is configured to emit strong light in the near-infrared region, and which is capable of detecting biological information, and is preferred for bioimaging.

Abstract: A sealant is provided for sealing a puncture through tissue that includes an elongate first section including a proximal end, a distal end, and a cross-section sized for delivery into a puncture through tissue, and a second section fused to and extending from the distal end of the first section. The first section may be formed from a freeze-dried hydrogel that expands when exposed to physiological fluid within a puncture. The second section may be formed from a solid mass of non-freeze-dried, non-crosslinked hydrogel precursors, the precursors remaining in an unreactive state until exposed to an aqueous physiological, whereupon the precursors undergo in-situ crosslinking with one another to provide an adhesive layer bonded to the first section. Apparatus and methods for delivering the sealant into a puncture through tissue are also provided.

Abstract: One embodiment of the present invention relates to a nanoemulsion and a preparation method therefor, the nanoemulsion comprising an oil component, a surfactant, and an aqueous component, wherein the aqueous component comprises a water-soluble active ingredient, a polysaccharide, and hyaluronic acid.

Abstract: The purpose of the present invention is to provide a novel amide alcohol that can be used as a cosmetic base ingredient. An amide alcohol represented by formula (I).

Abstract: Provided are radiopaque compositions comprising one or more of yttrium (Y), strontium (Sr), gallium (Ga), and silicon, or oxides and salts thereof. The composition can comprise a combination of Y2O3, SrO, Ga2O3, and SiO2, and optionally MnO2, and TiO2. Other compositions comprise SrO, Ga2O3, TiO2, MnO2, and SiO2. The composition can be a particulate material. The compositions are useful for radioembolization to treat tumors.

Abstract: The invention provides a cerebral nitric oxide donor for use in a method for assessing the extent of brain dysfunction following brain injury, said method comprising contacting at least a portion of the brain of a subject with a brain injury with said cerebral nitric oxide donor and determining whether or not there is a subsequent change in one or more aspects of brain physiology, wherein the extent by which said one or more aspects of brain physiology improves is indicative of the extent of brain dysfunction.

Abstract: Generally spherical resin particles formed of a thermoplastic resin, having a sphericity of 0.90 to 1.00, a light scattering index of 0.5 to 1.0 and a linseed oil absorption of 30 to 150 mL/100 g.

Abstract: Hypertonic pharmaceutical compositions are disclosed. The hypertonic pharmaceutical compositions contain an anti-platinum chemoprotectant agent and a gelling agent. Also disclosed are methods of medical use of the hypertonic pharmaceutical compositions.